Publications

5808 Results

SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer

Authors
RB Natale;HB Grossman;B Blumenstein;N Vogelzang;DL Trump;VO Speights;R deVere White;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 20:2a(#3)
Year
2001
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

Does a prior radical prostatectomy (RP) alter outcome of hormonal therapy for metastatic (M+) prostate cancer (CAP)

Authors
IM Thompson;J Basler;C Tangen;ED Crawford
Journal / Conference
Journal of Urology 165(5)Suppl:168(#689)
Year
2001
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8894 (INT-0105) (EST-2889)

Nephrectomy followed by interferon alfa 2-b compared with interferon alfa-2b alone for metastatic renal-cell cancer

Authors
RC Flanigan;SE Salmon;BA Blumenstein;SI Bearman;V Roy;PC McGrath;JR Caton, Jr;N Munshi;ED Crawford
Journal / Conference
New England Journal of Medicine 345(23):1655-1659
Year
2001
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8949

Molecular epidemiologic studies within the selenium and vitamin E cancer prevention trial (SELECT)

Authors
A Hoque;D Albanes;SM Lippman;MR Spitz;PR Taylor;EA Klein;IM Thompson;P Goodman;JL Stanford;JJ Crowley;CA Coltman;RM Santella
Journal / Conference
Cancer Causes and Control 12:627-633
Year
2001
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

The prostate cancer prevention trial: current status and lessons learned

Authors
IM Thompson;M Kouril;EA Klein;CA Coltman;A Ryan;P Goodman
Journal / Conference
Urology 57(Suppl.4A):230-234
Year
2001
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of Intergroup trial E1694/S9512/C509801

Authors
JM Kirkwood;JG Ibrahim;JA Sosman;VK Sondak;SS Agarwala;MS Ernstoff;U Rao
Journal / Conference
Journal of Clinical Oncology 19(9):2370-2380
Year
2001
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9512 (E1694)

Updated results of a prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast ca involving 10 or more axillary lymph nodes: CALGB 9082/SWOG 9114/NCIC Ma-13

Authors
WP Peters;G Rosner;J Vredenburgh;E Shpall;M Crump;L Marks;C Cirrincione;D Hurd;L Norton
Journal / Conference
Proc of the American Society of Clinical Oncology 20:21a(#81)
Year
2001
Research Committee(s)
Breast
Study Number(s)
SWOG-9114 (INT-0163) (CALGB-9082)

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial

Authors
PJ Loehrer;M Jiroutek;S Aisner;J Aisner;M Green;CR Thomas;R Livingston;DH Johnson
Journal / Conference
Cancer 91(11):2010-2015
Year
2001
Research Committee(s)
Lung
Study Number(s)
SWOG-9449 (INT-0156) (E1C93)

Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626

Authors
JW Goodwin;SJ Green;S Giarritta;JK Giguere;K Hoelzer;J Bearden;RB Livingston;J Gralow;PA Ganz;S Martino;KS Albain
Journal / Conference
Breast Cancer Research and Treatment 69(3):292(#462)
Year
2001
Research Committee(s)
Breast
Study Number(s)
S9626

A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BudR for the treatment of anaplastic astrocytoma.

Authors
M Prados;W Seiferheld;H Sandler;J Buckner;T Phillips;C Schultz;R Urtasun;R Davis;P Gutin;H Greenburg
Journal / Conference
Int J Radiat Oncol Biol Phys 51(3):207(#1062)
Year
2001
Research Committee(s)
Brain
Study Number(s)
SWOG-9340 (RTOG-9404)